The blind men and the AML elephant: can we feel the progress?

Personalizing Chinese medicine by integrating molecular features of diseases and herb ingredient information: application to acute myeloid leukemia. Oncotarget (2017) 0.75

International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood (1997) 20.41

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol (2009) 12.41

Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med (2009) 6.67

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol (2012) 5.52

Acute promyelocytic leukemia: from highly fatal to highly curable. Blood (2008) 5.35

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood (2013) 4.85

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer (2007) 4.60

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol (2010) 4.12

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet (2012) 4.03

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood (2013) 3.91

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol (2006) 3.50

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood (2015) 2.43

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res (2001) 2.35

Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol (2011) 2.19

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol (2014) 2.15

Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood (2006) 2.12

Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol (2009) 1.98

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol (2015) 1.69

Defining best supportive care. J Clin Oncol (2008) 1.60

A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood (2015) 1.58

Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol (2012) 1.57

Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol (2013) 1.52

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. Br J Haematol (2001) 1.42

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia (2012) 1.39

Value-Based Cancer Care. N Engl J Med (2015) 1.06

Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. J Clin Oncol (2016) 1.02

Improving the methodologic and ethical validity of best supportive care studies in oncology: lessons from a systematic review. J Clin Oncol (2009) 0.96

Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation? Hematology Am Soc Hematol Educ Program (2013) 0.96

New Math on Drug Cost-Effectiveness. N Engl J Med (2015) 0.95

Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia. Ann Hematol (2014) 0.90

SAB--a promising new treatment to improve remission rates in AML in the elderly? Br J Haematol (2002) 0.87

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood (2016) 0.85

New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine. Clin Cancer Res (2014) 0.83

New insights in AML biology from genomic analysis. Semin Hematol (2014) 0.81

Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities. Am J Hematol (2015) 0.81

Caution using hypomethylating agents in myelodysplasia or myeloid leukemia with complex cytogenetics. J Clin Oncol (2010) 0.80

Daunorubicin in the therapy of acute granulocytic leukemia. Cancer Res (1973) 0.79

Other problems with phase III best supportive care studies. J Clin Oncol (2009) 0.77

A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia. Leukemia (2014) 0.76